Yvonne Diaz (@yvonne_diaz_) 's Twitter Profile
Yvonne Diaz

@yvonne_diaz_

Comms professional. Mum to twin sons & a dog. Living w stage 4 ALK+ #lungcancer. Co-founder @OncogeneCancer. Board Member @ALKPositiveInc #ResearchMatters #LCSM

ID: 1515061275088150528

linkhttps://instagram.com/yvonne_diaz_lc?igshid=OGQ5ZDc2ODk2ZA== calendar_today15-04-2022 20:15:47

2,2K Tweet

1,1K Followers

862 Following

OncoDaily (@oncodaily) 's Twitter Profile Photo

🫁Radioligand Therapy Offers Hope to Lung Cancer Patients - Oncogene Cancer Research oncodaily.com/insight/148167 #Cancer #LCSM #CancerTreatment #Innovation #MedEd #MedNews #Health #Medicine #MedTwitter #OncoDaily #Oncology

Christian Rolfo (@christianrolfo) 's Twitter Profile Photo

Today is the #WorldCancerResearchDay a great opportunity to celebrate all the discoveries and big steps that allow advance in patient care. Proud of our team at The James Ohio State Medical Oncology and their amazing contributions in the field.

Today is the  #WorldCancerResearchDay a great opportunity to celebrate all the discoveries and big steps that allow advance in patient care. Proud of our team at <a href="/OSUCCC_James/">The James</a> <a href="/OhioStateMedOnc/">Ohio State Medical Oncology</a> and their amazing contributions in the field.
ALK Positive (@alkpositiveinc) 's Twitter Profile Photo

Our next ALKtALK is this Sunday (9/29) at 5pm ET. Dr. JessicaJLinMD will provide an update on the #research highlights from IASLC #WCLC24 & #ESMO24 conferences. As usual, she'll also take questions from our ALK+ cancer community. Don't miss this! See alkpositive.org/alktalk

Our next ALKtALK is this Sunday (9/29) at 5pm ET.  Dr. <a href="/JessicaJLinMD/">JessicaJLinMD</a> will provide an update on the #research highlights from <a href="/IASLC/">IASLC</a> #WCLC24 &amp; #ESMO24 conferences.  As usual, she'll also take questions from our ALK+ cancer community.

Don't miss this!  See alkpositive.org/alktalk
Oncogene Cancer Research (@oncogenecancer) 's Twitter Profile Photo

Mel, a mum of 3 living in E London w her partner Sarah, had an x-ray to confirm Long Covid when a tumour was found. It turned out to be 'curable' EGFR lung cancer. 4 yrs later Mel's now stage 4. Read more & why she believes in the power of research oncogeneresearch.org/mels-story #LCSM

Mel, a mum of 3 living in E London w her partner Sarah, had an x-ray to confirm Long Covid when a tumour was found. It turned out to be 'curable' EGFR lung cancer. 4 yrs later Mel's now stage 4. 

Read more &amp; why she believes in the power of research
oncogeneresearch.org/mels-story #LCSM
Dhru Deb, PhD (@cancersciartist) 's Twitter Profile Photo

Our symposium for lung cancer patients & caregivers, discussing where research addresses unmet needs for immunotherapy, palliative care, telemedicine, KRAS, advocacy, small-cell and brain metastasis. Register & get ready with your questions for this amazing panel on Nov 4. #lcsm

Tejas Patil (@tejaspatilmd) 's Twitter Profile Photo

Fantastic work from Davare Lab on oncogenic potential of #ROS1 extracellular domain (ECD) which doesn’t necessarily require fusion partner to sustain oncogenesis. The ROS1ders, Inc.

Yvonne Diaz (@yvonne_diaz_) 's Twitter Profile Photo

Tonight's ALKtALK with Dr. JessicaJLinMD has just kicked off at the earlier time than usual. Do join us to hear all the latest research unveiled during #WCLC24 & #ESMO24, and a general talk on all things ALK lung cancer. Join us now: 👉alkpositive.org/alktalk

Yvonne Diaz (@yvonne_diaz_) 's Twitter Profile Photo

Following the latest CROWN data, those w ALK lung cancer want to understand what resistance to first line Lorlatinib looks like & any next 2L therapy. While the data is not quite there, Dr. JessicaJLinMD shared this initial info from #WCLC24. The ALKtALK replay out soon. #LCSM

Following the latest CROWN data, those w ALK lung cancer want to understand what resistance to first line Lorlatinib looks like &amp; any next 2L therapy. While the data is not quite there, Dr. <a href="/JessicaJLinMD/">JessicaJLinMD</a> shared this initial info from #WCLC24.

The ALKtALK replay out soon. #LCSM
ALK Positive (@alkpositiveinc) 's Twitter Profile Photo

Yvonne Diaz JessicaJLinMD IASLC ESMO - Eur. Oncology MassGeneral News Summer Farmen At last evening's ALKtALK, this chart generated a lot of questions. Important to understand why not all ALK patients move to a second line inhibitor after their first line treatment. Stay tuned for the replay of our ALKtALK - out this week. Thanks Dr. JessicaJLinMD! #LCSM

<a href="/Yvonne_Diaz_/">Yvonne Diaz</a> <a href="/JessicaJLinMD/">JessicaJLinMD</a> <a href="/IASLC/">IASLC</a> <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/MassGeneralNews/">MassGeneral News</a> <a href="/Sunonmyhip/">Summer Farmen</a> At last evening's ALKtALK, this chart generated a lot of questions. Important to understand why not all ALK patients move to a second line inhibitor after their first line treatment.

Stay tuned for the replay of our ALKtALK - out this week. Thanks Dr. <a href="/JessicaJLinMD/">JessicaJLinMD</a>! #LCSM
EGFR Resisters (@egfrresisters) 's Twitter Profile Photo

Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas nature.com/articles/s4139…

Yvonne Diaz (@yvonne_diaz_) 's Twitter Profile Photo

Repurposing approved meds may speed up options for patients. Gilteritinib is FDA-approved for FLT3-mutated AML. U-M Rogel Cancer Center is studying use of gilteritinib in ALK. Article shows cholesterol inhibition enhances response of gilteritinib in lung cancer👇 nature.com/articles/s4141…

Oncogene Cancer Research (@oncogenecancer) 's Twitter Profile Photo

Wonderful to gather in Madrid for the semi-annual LuCE members meeting under the theme “Unlocking our collective power.” Great to see so many new members joining to use our collective voices to improve lung cancer outcomes. #StrongerTogether#LCSM

Sai-Hong Ignatius Ou (@oncooulungca) 's Twitter Profile Photo

Systematic review & network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as 1L treatment for advanced ALK-NSCLC. lungcancerjournal.info/article/S0169-… ALK+ International ALK Positive LCAM Coalition

UKALK+ (@ukalk1) 's Twitter Profile Photo

Great interactive day 2 at the Lung Cancer Europe Members meeting sharing best practice and there have been some great initiatives we have heard about. Great being one of the ‘oncogene girls’ representing the UK 😉EGFR Positive Lung Cancer UK Oncogene Cancer Research Lung Cancer Europe

Great interactive day 2 at the <a href="/LungCancerEu/">Lung Cancer Europe</a> Members meeting sharing best practice and there have been some great initiatives we have heard about. Great being one of the ‘oncogene girls’ representing the UK 😉<a href="/EgfrUk/">EGFR Positive Lung Cancer UK</a> <a href="/OncogeneCancer/">Oncogene Cancer Research</a> <a href="/LungCancerEu/">Lung Cancer Europe</a>
Dr Anne-Marie Baird (@bairdam) 's Twitter Profile Photo

Two brilliant days with this exceptional group of individuals. Thank you to our speakers, members, executive team & our moderator/facilitator - Kathy Redmond. Special thanks to my fellow board members. It's my privilege serving as your Lung Cancer Europe president ❤️

Two brilliant days with this exceptional group of individuals. Thank you to our speakers, members, executive team &amp; our moderator/facilitator - Kathy Redmond. Special thanks to my fellow board members. It's my privilege serving as your <a href="/LungCancerEu/">Lung Cancer Europe</a> president ❤️
Oncogene Cancer Research (@oncogenecancer) 's Twitter Profile Photo

Great to see a blood test for the detection of lung cancer is one step closer w the work from University of York’s Cizzie Biotech & Moffitt Cancer Center. Based on the discovery of the CIZ1B biomarker. A step fwd in early detection. york.ac.uk/news-and-event…